Beta
Back to LLY.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • Revenue by Segments
  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
cash-and-debt-chart

LLY Cash & Debt

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

As of Q4'25, Eli Lilly's (LLY) cash and short-term investments stood at $7.27B, reflecting a decline from the peak of $9.91B in Q3'25, while total debt remained stable at $42.50B, resulting in a net debt position of approximately $35.23B. This latest data point indicates a temporary liquidity dip following a significant cash influx in the prior quarter, with debt levels showing minimal fluctuation. Over the period from Q1'23 to Q4'25, cash and short-term investments exhibited volatility, starting at $3.67B and declining to a low of $2.49B in Q3'23 before recovering steadily to reach $9.91B in Q3'25, driven by apparent operational cash flows or financing activities. In contrast, debt trended upward consistently from $18.88B in Q1'23 to $42.50B in Q4'25, with notable accelerations in 2024 and early 2025, suggesting aggressive borrowing possibly for investments or acquisitions; overall, the net debt has widened significantly, highlighting increasing leverage amid fluctuating liquidity.